Wearing-off scales in Parkinson's disease: Critique and recommendations

Movement Disorders

Volumn 26, Issue 12, 2011, Pages 2169-2175

  Antonini, Angelo ^a   Martinez Martin, Pablo ^b   Chaudhuri, Ray K ^c   Merello, Marcelo ^d   Hauser, Robert ^e   Katzenschlager, Regina ^f   Odin, Per ^g   Stacy, Mark ^h   Stocchi, Fabrizio ⁱ   Poewe, Werner ^j   Rascol, Oliver ^k   Sampaio, Cristina ^l   Schrag, Anette ^m   Stebbins, Glenn T ⁿ   Goetz, Christopher G ^o  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d FLENI   (Argentina)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f DANUBE HOSPITAL   (Austria)

^g Central Hospital   (Germany)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ IRCCS SAN RAFFAELE PISANA   (Italy)

^j UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^k Laboratoire de Pharmacologie Medicale et Clinique   (France)

^l Lisbon School of Medicine   (Portugal)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Clinimetrics; Parkinson's disease; Psychometrics; Rating scales; Reliability; Validity; Wearing off

Indexed keywords

CORE ASSESSMENT PROGRAM FOR SURGICAL INTERVENTIONAL THERAPIES IN PARKINSON DISEASE SCALE; DIAGNOSTIC TEST; DISEASE SEVERITY; FLORIDA SURGICAL QUESTIONNAIRE FOR PARKINSON DISEASE; HUMAN; MOTOR FLUCTUATION DIARY SCALE; MOVEMENT DISORDER SOCIETY UNIFIED PARKINSON DISEASE RATING SCALE; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RELIABILITY; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE SCALE; UNIFIED PARKINSON DISEASE RATING SCALE; VALIDITY; WEARING OFF QUEST QUESTIONNAIRE;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; HUMANS; PARKINSON DISEASE; PSYCHOMETRICS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; WEIGHTS AND MEASURES;

EID: 80055089035     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23875     Document Type: Review

References (39)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001; 16: 448-458.
2. Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother. 2006; 7: 1399-1407.
3. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology. 2002; 59: 408-413.
4. Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol. 2010; 63: 257-266.
5. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004; 351: 2498-2508.
6. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol. 2005; 252(Suppl 4): IV37-IV42.
7. Leentjens AF, Dujardin K, Marsh L, et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008; 23: 2015-2025.
8. Leentjens AF, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008; 23: 2004-2014.
9. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007; 22: 1077-1092.
10. Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord. 2008; 23: 484-500.
11. Colosimo C, Martinez-Martin P, Fabbrini G, et al. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord. 2010; 25: 1131-1142.
12. Friedman JH, Alves G, Hagell P, et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010; 25: 805-822.
13. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23: 2129-2170.
14. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005; 20: 726-733.
15. Stacy M, Hauser R. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease. J Neural Transm. 2007; 114: 211-217.
16. Stacy M, Hauser R, Oertel W, et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol. 2006; 29: 312-321.
17. Martinez-Martin P, Tolosa E, Hernandez B, Badia X. Validation of the "QUICK" questionnaire-a tool for diagnosis of "wearing-off" in patients with Parkinson's disease. Mov Disord. 2008; 23: 830-836.
18. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information; 1987: 153-163.
19. Okun MS, Fernandez HH, Pedraza O, et al. Development and initial validation of a screening tool for Parkinson disease surgical candidates. Neurology. 2004; 63: 161-163.
20. Santens P, de Noordhout AM. Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey. Acta Neurol Belg. 2006; 106: 137-141.
21. Martinez-Martin P, Tolosa E, Hernandez B, Badia X. The Patient Card questionnaire to identify wearing-off in Parkinson disease. Clin Neuropharmacol. 2007; 30: 266-275.
22. Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord. 2008; 14: 205-212.
23. Eggert K, Skogar O, Amar K, et al. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. J Neural Transm. 2010; 117: 333-342.
24. Stacy M. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. J Neural Transm. 2010; 117: 837-846.
25. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005; 76: 1640-1644.
26. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003; 18: 738-750.
27. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005; 64: 216-223.
28. Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand. 2009; 119: 345-348.
29. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord. 2007; 22: 1145-1149.
30. Goetz CG, Stebbins GT, Blasucci LM, Grobman MS. Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov Disord. 1997; 12: 1039-1041.
31. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000; 23: 75-81.
32. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord. 2004; 19: 1409-1413.
33. Reimer J, Grabowski M, Lindvall O, Hagell P. Use and interpretation of on/off diaries in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004; 75: 396-400.
34. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005; 365: 947-954.
35. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005; 62: 241-248.
36. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008; 23: 2177-2185.
37. Lewitt PA, Guttman M, Tetrud JW, et al. Adenosine A(2A) receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008; 63: 295-302.
38. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007; 6: 513-520.
39. Lyons KE, Pahwa R. Electronic motor function diary for patients with Parkinson's disease: a feasibility study. Parkinsonism Relat Disord. 2007; 13: 304-307.